Meliambro K, He JC, Campbell KN. Podocyte-targeted therapies - progress and future directions , Nat Rev Nephrol, 20(10): 2024,643-658

Cantarelli C, Campbell KN, Cravedi P. Parietal epithelial cells in glomerulosclerosis: a new piece in the puzzle? , J Nephrol: 2024

de Cos M, Mosoyan G, Chauhan K, Troost JP, Wong JS, Lefferts S, Morgan P, Meliambro K, Egerman M, Ray J, Parker T, Levine D, Seshan S, Bardash Y, Horowitz B, Kent CA, Shaw MM, Perlman A, Moledina DG, Coca SG, Campbell KN. Urinary Plasminogen as a Marker of Disease Progression in Human Glomerular Disease , Am J Kidney Dis, 84(2): 2024,205-214.e1

Li J, Wisnivesky JP, Lin JJ, Campbell KN, Hu L, Kale MS. Examining the Trajectory of Health-Related Quality of Life among Coronavirus Disease Patients , J Gen Intern Med, 39(10): 2024,1820-1827

Suresh V, Stillman IE, Campbell KN, Meliambro K. Focal Segmental Glomerulosclerosis , Adv Kidney Dis Health, 31(4): 2024,275-289

Jhaveri KD, Campbell KN, Gibson KL. Nephrotic Syndrome: Have We Entered a New Era? , Adv Kidney Dis Health, 31(4): 2024,265-266

Campbell KN, Gibson KL, Jhaveri KD. Nephritic Syndromes: A Lot to Progress , Adv Kidney Dis Health, 31(3): 2024,167-169

Campbell KN, Gesualdo L, Murphy E, Rheault MN, Srivastava T, Tesar V, Komers R, Trachtman H. Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety , Kidney Med, 6(6): 2024,100833

Campbell KN, Griffin S, Trachtman H, Geletka R, Wong MG. Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice , Int J Nephrol Renovasc Dis, 16: 2023,281-291

Shilane D, Miller S, Fleming J, Bar J, Corbin Y, Garcia M, Gasner MR, Campbell KN, Brown S, Weber E. Barriers to Telehealth Utilization Among Patients of Limited Income with Chronic Conditions and a Gap in Care , Telemed J E Health, 29(11): 2023,1659-1666